Rankings
▼
Calendar
▼
DMII Q2 2025 Earnings Report — Drugs Made In America Acquisition II Corp. Ordinary Shares Revenue & Financial Results | Market Cap Arena
Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII
Q2 2025 Earnings
Reported June 30, 2025
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q2 2025
Q1 2025
Q2 2024
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$38.1K
-$59.3K
—
35.8%
—
EPS (Diluted)
$0.00
$-0.00
—
100.0%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$0
Selling & Marketing
$0
General & Administrative
$38.1K
SG&A Expenses
$38.1K
Other Expenses
$0
Operating Expenses
$38.1K
Cost & Expenses
$38.1K
OPERATING INCOME
-$38.1K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$38.1K
Income Tax Expense
$0
Net Income from Continuing Ops
-$38.1K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$38.1K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$38.1K
D&A
$0
EBIT
-$38.1K
EBITDA
-$38.1K
EPS
$0
EPS Diluted
$0
marketcaparena.com
Balance Sheet
Item
Amount
Cash & Equivalents
$4.4K
Short-Term Investments
$0
Net Receivables
$2.6K
Inventory
$0
Other Current Assets
$0
TOTAL CURRENT ASSETS
$11.6K
PP&E (Net)
$0
Goodwill
$0
Intangible Assets
$0
Long-Term Investments
$0
Tax Assets
$0
Other Non-Current Assets
$101.8K
TOTAL NON-CURRENT ASSETS
$101.8K
TOTAL ASSETS
$113.4K
Account Payables
$0
Short-Term Debt
$297.3K
Deferred Revenue
$0
Other Current Liabilities
$0
TOTAL CURRENT LIABILITIES
$327.5K
Long-Term Debt
$0
Deferred Revenue NC
$0
Deferred Tax Liabilities
$0
Other Non-Current Liabilities
$0
TOTAL NON-CURRENT LIABILITIES
$0
TOTAL LIABILITIES
$327.5K
Common Stock
$1.4K
Additional Paid-In Capital
$33.6K
Retained Earnings
-$249.1K
Treasury Stock
$0
Accum. Other Comp. Income
$0
Other Equity
$0
TOTAL STOCKHOLDERS' EQUITY
-$214.1K
Minority Interest
$0
TOTAL EQUITY
-$214.1K
TOTAL LIABILITIES & EQUITY
$113.4K
Total Debt
$297.3K
Net Debt
$292.9K
marketcaparena.com
← Q1 2025
DMII Overview
Q3 2025 →